Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal caricinoma: Docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin

Chinese Journal of Cancer

Volumn 29, Issue 2, 2010, Pages 140-144

  Lu, Xing ^a   Guo, Xiang ^a   Hong, Ming Huang ^a   Chen, Qiu Yan ^a   Zeng, Qi ^a   Xiang, Yan Qun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adverse events; Docetaxel; Efficacy; Nasopharyngeal neoplasm

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBOPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEG EDEMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEUTROPENIA; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; WEIGHT GAIN;

EID: 78149298020     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10433     Document Type: Article

References (18)

1. AI-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099 [J]. J Clin Oncol, 1998, 16 (4):1310-1317.
2. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J]. J Clin Oncol, 2004, 22(13): 2643-2653.
3. Ogawa T, Terada A, Hyodo I, et al. A Phase I study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck [J]. Gan To Kagaku Ryoho, 2005, 32(7):977-981.
4. Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA [J]. J Clin Oncol, 2004, 22(15):3053-3060.
5. Baujat B, Bourhis J, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients [J]. Int J Radiat Oncol Biol Phys, 2006, 64:47-56.
6. Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature [J]. J Clin Oncol, 2004, 22(22):4604-4612.
7. Nabell L, Spencer S. Docetaxel with concurent radiotherapy in head and neck cancer [J]. Semin Oncol, 2003, 30(6 Suppl 18):89-93.
8. Hehr T, Classen J, Belka C, et al. Radiation alternating with docetaxel and cisplatin in inoperable recurence of head and neck cancer: a prospective phase I /II trial [J]. Int J Radiat Oncol Biol Phys, 2005, 61 (5):1423-1431.
9. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [J]. J Clin Oncol, 2009, 27(2): 242-249.
10. Douple EB, Richmond RC, O'Hara JA, et al. Carboplatin as a potentiator of radiation therapy [J]. Cancer Treat Rev, 1985, 12(Suppl A):111-124.
11. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections for new trials, and the emergence of carboplatin [J]. Semin Oncol, 1989, 16(4 Suppl 6):31-43.
12. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma [J]. J Natl Cancer Inst, 1999, 91 (24):2081-2086.
13. Calais G, Le Floch O. Concomitant radiotherapy and chemotherapy in the treatment of cancer of the upper respiratory and digestive tracts [J]. Bull Cancer Radiother, 1996, 83(4):321-329.
14. Muggia FM. Overview of carboplatin: Replacing complementing and extending the therapeutic horizons of cisplatin [J]. Semin Oncol, 1989, 16 (2 Suppl 5):7-13.
15. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial [J]. Eur J Cancer, 2007, 43(9):1399-1406.
16. Tsukuda M, Mikami Y, Tanigaki Y, et al. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracill for patients with locally advanced squamous cell carcinoma of the head and neck [J]. Int J Clin Oncol, 2004, 9(3):l6l-166.
17. Genet D, Cupissol D, Calais G, et al. Docetaxel plus 5-fluomuracill in locally recurent and/or metastatic squareous cell carcinoma of the head and neck: a phase II multicenter study [J]. Am J Clin Oncol, 2004, 27(5): 472-476.
18. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer [J]. N Engl J Med, 2007, 357(17): 1705-1715.